Carcinoma of the Breast Ii-Criteria of Operability (Continued)

Haagensen, C. D.; Stout, Arthur Purdy

doi:10.1097/00000658-194312000-00010

Cited by 156 publications

(100 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with locally advanced disease (defined as inoperable by the Haagensen criteria (Haagensen and Stout, 1943)) or inflammatory breast cancer were excluded from this analysis. Patients were only eligible if the diagnosis had been confirmed histologically (by core biopsy) prior to commencement of chemotherapy, and they had undergone surgery following chemotherapy.…”

Section: Patient Selectionmentioning

confidence: 99%

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

et al. 2004

View full text Add to dashboard Cite

The aim of this study was to ascertain if oestrogen receptor (ER) status predicts for pathological complete response (pCR) to neoadjuvant chemotherapy in operable breast cancer, and the effects of pCR on survival. Using a single-institution database, 435 patients were identified, who received neoadjuvant chemotherapy for operable breast cancer and were eligible for the analysis. Patients whose tumours were ER negative were more likely to achieve a pCR than patients who were ER positive (21.6 vs 8.1%, Po0.001). Owing to a strong correlation between ER status and grade, these variables were not shown to be independent predictors of pCR. Overall survival (OS) was better in those patients who achieved a pCR compared to those who did not (5-year OS 91 vs 73%; P ¼ 0.02). This was still the case when only patients with ER-negative tumours were examined (5-year OS 90 vs 52%, P ¼ 0.005), but not in the subset of patients with ER-positive tumours (5-year OS 93 vs 79%; P ¼ 0.3). Therefore, patients with ERnegative tumours were found to be more likely to achieve a pCR to neoadjuvant chemotherapy than those with ER-positive tumours, and pathological response did not have prognostic significance in patients with ER-positive tumours.

show abstract

Section: Patient Selectionmentioning

confidence: 99%

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Further investigations were performed if clinically indicated. Patients with locally advanced disease (defined as inoperable by the Haagensen criteria) or inflammatory breast cancer were excluded from this analysis (Haagensen and Stout, 1943).…”

Section: Patient Characteristicsmentioning

confidence: 99%

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

et al. 2006

View full text Add to dashboard Cite

Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma have a better overall survival than those with residual disease. Many classification systems assessing pathological response to neoadjuvant chemotherapy include residual ductal carcinoma in situ (DCIS) only in the definition of pathological complete response. The purpose of this study was to investigate whether patients with residual DCIS only have the same prognosis as those with no residual invasive or in situ disease. A retrospective analysis of a prospectively maintained database identified 435 patients, who received neoadjuvant chemotherapy for operable breast cancer between February 1985 and February 2003. Of these, 30 (7%; 95% CI 5 -9%) had no residual invasive disease or DCIS and 20 (5%; CI 3 -7%) had residual DCIS only. With a median follow-up of 61 months, there was no statistical difference in disease-free survival, 80% (95% CI 60 -90%) in those with no residual invasive or in situ disease and 61% (95% CI 35 -80%) in those with DCIS only (P ¼ 0.4). No significant difference in 5-year overall survival was observed, 93% (95% CI 75 -98%) in those with no residual invasive or in situ disease and 82% (95% CI 52 -94%) in those with DCIS only (P ¼ 0.3). Due to the small number of patients and limited number of events in each group, it is not possible to draw definitive conclusions from this study. Further analyses of other databases are required to confirm our finding of no difference in disease-free and overall survival between patients with residual DCIS and those with no invasive or in situ disease following neoadjuvant chemotherapy for breast cancer.

show abstract

“…The criteria for locally advanced breast cancer were those reported by Haagensen and Stout (1943). Inflammatory breast cancer was defined as a T4 lesion with diffuse brawny induration of the breast with an erysipeloid edge (Beahrs et al, 1992 …”

mentioning

confidence: 99%

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen

Bonnefoi

Smith²,

O’Brien³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so- (Smith et al., 1995). The schedule has also shown high activity in the treatment of advanced gastric carcinoma with a response rate of 71% (Findlay et al., 1994).The underlying rationale for this schedule is as follows: Phase I studies have demonstrated that 5-FU can be administered by protracted continuous infusion at a dose of 300 mg m-2 day-' without interruption for up to 60 days or up to 36 g cumulative dose (Lokich et al., 1981); response rates of up to 53% have been reported in patients with metastatic breast cancer extensively pretreated with chemotherapy (Huan et al., 1989). This represents a more than 3-fold increase in response compared with conventional studies. In an overview of six phase II studies involving 182 patients with refractory breast cancer, most of whom were pretreated with bolus 5-FU, an average response rate of 29% (range 17-53%) has been reported (Hansen, 1991). As originally suggested in the phase I study by Lokich and subsequently confirmed by phase II studies, myelosuppression, an important toxic effect occurring with bolus administration, is rarely reported with infusional 5-FU and the dose-limiting toxicities are stomatitis, diarrhoea and plantar-palmar erythema (Lokich et al

show abstract

Carcinoma of the Breast Ii-Criteria of Operability (Continued)

Cited by 156 publications

References 3 publications

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen

Contact Info

Product

Resources

About